421 related articles for article (PubMed ID: 18929734)
1. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
[TBL] [Abstract][Full Text] [Related]
2. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
3. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
[TBL] [Abstract][Full Text] [Related]
4. The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs.
McAdams M; Staffa JA; Dal Pan GJ
Contraception; 2007 Oct; 76(4):278-81. PubMed ID: 17900437
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
7. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
8. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
10. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Blode H; Schürmann R; Benda N
Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
[TBL] [Abstract][Full Text] [Related]
11. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
12. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
Dinger JC; Heinemann LA; Kühl-Habich D
Contraception; 2007 May; 75(5):344-54. PubMed ID: 17434015
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
14. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
15. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
16. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores.
Eng PM; Seeger JD; Loughlin J; Clifford CR; Mentor S; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):297-305. PubMed ID: 18215000
[TBL] [Abstract][Full Text] [Related]
17. Safety of a new oral contraceptive containing drospirenone.
Heinemann LA; Dinger J
Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
[TBL] [Abstract][Full Text] [Related]
18. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
Blode H; Foidart JM; Heithecker R
Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
[TBL] [Abstract][Full Text] [Related]
19. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial.
Giribela CR; Melo NR; Silva RC; Hong VM; Guerra GM; Baracat EC; Consolim-Colombo FM
Contraception; 2012 Jul; 86(1):35-41. PubMed ID: 22465116
[TBL] [Abstract][Full Text] [Related]
20. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women.
Paoletti AM; Orrù M; Lello S; Floris S; Ranuzzi F; Etzi R; Zedda P; Guerriero S; Fratta S; Sorge R; Mallarini G; Melis GB
Contraception; 2004 Oct; 70(4):293-8. PubMed ID: 15451333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
